ReviewFrontiers in immunology2026
The microbiota-NK cell axis in colorectal cancer: a spatial and subset-centric framework.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota and natural killer (NK) cells jointly shape colorectal cancer (CRC) progression and immunotherapy response, yet existing reviews largely adopt a linear, pathogen-centric view that overlooks NK-cell heterogeneity and spatial tumor microenvironment architecture. We propose an integrated framework centered on three progressive pillars: (i) the microbiota appears to selectively shape three well-characterized NK-cell states (activated, dysfunctional, and memory-like), with a fourth regulatory-like state that remains mechanistically uncharacterized through metabolically and genetically mediated mechanisms; (ii) emerging spatial evidence suggests beneficial commensals and activated NK cells preferentially localize to perivascular niches, whereas pathogenic bacteria and dysfunctional NK cells are enriched within the tumor parenchyma, though multicenter validation is needed; and (iii) these insights support two testable patient-stratification strategies for future clinical testing, an "enrichment" approach for tumors with pre-existing activated NK signatures, and a "remodeling" approach for Fusobacterium nucleatum (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.